# Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

> **NCT03178071** · — · NO_LONGER_AVAILABLE · sponsor: **Pfizer**

## Conditions studied

- Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT03178071
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2019-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03178071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03178071, "Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03178071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*